虚弱性及其对心力衰竭的影响:对预后和治疗的影响
Khawaja M Talha1, Stephen J Greene2, Javed Butler3
1Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
Heart failure clinics
|August 31, 2024
概括
虚弱影响心力衰竭与减少喷射率 (HFrEF) 患者,增加死亡风险. 尽管人们担心治疗不足,但证据支持HFrEF疗法在脆弱个体中的安全性.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 内部医学 内部医学
背景情况:
- 大约50%的心力衰竭患者患有心力衰竭和减少喷射率 (HFrEF) 的患者患有脆弱性.
- 在HFrEF患者中,虚弱显著增加死亡风险 (约2倍).
- 在脆弱性和HFrEF相互加剧的情况下存在双向关系.
研究的目的:
- 审查目前关于医疗疗的安全性和有效性的证据,用于HFrEF的脆弱患者.
- 突出管理脆弱的HFrEF患者的挑战,包括治疗不足.
- 倡导多学科的方法,以优化护理和改善生活质量.
主要方法:
- 关于脆弱性和HFrEF现有研究的文献综述.
- 对临床试验数据关于脆弱人群中药物安全性的分析.
- 专家意见和临床指南的综合.
主要成果:
- 脆弱的HFrEF患者面临更高的死亡风险.
- 尽管风险较高,但由于安全问题,脆弱的患者往往接受不够的治疗.
- 目前的证据表明,针对HFrEF的指导方针导向医学疗法在老年脆弱患者中是安全的.
结论:
- 为脆弱的HFrEF患者优化基于证据的治疗方法至关重要.
- 多学科的团队方法对于有效的管理至关重要.
- 专注于目标导向治疗可以改善这些高风险个体的生活质量.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545


